Cargando…
Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO
Variants in hereditary cancer risk genes are frequently identified following tumor-based DNA sequencing and represent an opportunity to diagnose hereditary cancer. We implemented an automated hereditary cancer screening program in a large HMO for all patients who underwent tumor-based DNA sequencing...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020326/ https://www.ncbi.nlm.nih.gov/pubmed/36261688 http://dx.doi.org/10.1007/s10689-022-00317-w |
_version_ | 1784908233062744064 |
---|---|
author | Hoffman, Trevor L. Kershberg, Hilary Goff, John Holmquist, Kimberly J. Haque, Reina Alvarado, Monica |
author_facet | Hoffman, Trevor L. Kershberg, Hilary Goff, John Holmquist, Kimberly J. Haque, Reina Alvarado, Monica |
author_sort | Hoffman, Trevor L. |
collection | PubMed |
description | Variants in hereditary cancer risk genes are frequently identified following tumor-based DNA sequencing and represent an opportunity to diagnose hereditary cancer. We implemented an automated hereditary cancer screening program in a large HMO for all patients who underwent tumor-based DNA sequencing to identify patients with hereditary cancer and determine if this approach augmented existing genetic counseling approaches driven by personal/family history criteria. Regular automated searches of a centralized tumor DNA variant database were performed for ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PALB2, and/or PMS2 variants, and germline hereditary cancer gene panel testing was offered to patients with tumor variants who had never undergone germline testing. Patients completing germline testing due to their tumor DNA test results were considered part of the tumor DNA safety net. Patients previously completing germline testing via traditional genetic counseling and tumor DNA safety net were compared for demographics, tumor type, presence of germline pathogenic/likely pathogenic (P/LP) variant, and whether NCCN criteria were met for hereditary cancer genetic testing. Germline P/LP variants were common in both groups. Patients who received germline testing through traditional genetic counseling were more likely to have cardinal hereditary tumors than the tumor DNA safety net group. Patients identified with hereditary cancer through traditional genetic counseling were more likely to meet NCCN personal/family history criteria for germline testing than the tumor DNA safety net group (99% versus 34%). A universal tumor DNA safety net screen is an important diagnostic strategy which augments traditional genetic counseling approaches based on personal/family history. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10689-022-00317-w. |
format | Online Article Text |
id | pubmed-10020326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-100203262023-03-18 Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO Hoffman, Trevor L. Kershberg, Hilary Goff, John Holmquist, Kimberly J. Haque, Reina Alvarado, Monica Fam Cancer Original Article Variants in hereditary cancer risk genes are frequently identified following tumor-based DNA sequencing and represent an opportunity to diagnose hereditary cancer. We implemented an automated hereditary cancer screening program in a large HMO for all patients who underwent tumor-based DNA sequencing to identify patients with hereditary cancer and determine if this approach augmented existing genetic counseling approaches driven by personal/family history criteria. Regular automated searches of a centralized tumor DNA variant database were performed for ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PALB2, and/or PMS2 variants, and germline hereditary cancer gene panel testing was offered to patients with tumor variants who had never undergone germline testing. Patients completing germline testing due to their tumor DNA test results were considered part of the tumor DNA safety net. Patients previously completing germline testing via traditional genetic counseling and tumor DNA safety net were compared for demographics, tumor type, presence of germline pathogenic/likely pathogenic (P/LP) variant, and whether NCCN criteria were met for hereditary cancer genetic testing. Germline P/LP variants were common in both groups. Patients who received germline testing through traditional genetic counseling were more likely to have cardinal hereditary tumors than the tumor DNA safety net group. Patients identified with hereditary cancer through traditional genetic counseling were more likely to meet NCCN personal/family history criteria for germline testing than the tumor DNA safety net group (99% versus 34%). A universal tumor DNA safety net screen is an important diagnostic strategy which augments traditional genetic counseling approaches based on personal/family history. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10689-022-00317-w. Springer Netherlands 2022-10-20 2023 /pmc/articles/PMC10020326/ /pubmed/36261688 http://dx.doi.org/10.1007/s10689-022-00317-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Hoffman, Trevor L. Kershberg, Hilary Goff, John Holmquist, Kimberly J. Haque, Reina Alvarado, Monica Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO |
title | Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO |
title_full | Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO |
title_fullStr | Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO |
title_full_unstemmed | Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO |
title_short | Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO |
title_sort | next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large hmo |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020326/ https://www.ncbi.nlm.nih.gov/pubmed/36261688 http://dx.doi.org/10.1007/s10689-022-00317-w |
work_keys_str_mv | AT hoffmantrevorl nextgenerationuniversalhereditarycancerscreeningimplementationofanautomatedhereditarycancerscreeningprogramforpatientswithadvancedcancerundergoingtumorsequencinginalargehmo AT kershberghilary nextgenerationuniversalhereditarycancerscreeningimplementationofanautomatedhereditarycancerscreeningprogramforpatientswithadvancedcancerundergoingtumorsequencinginalargehmo AT goffjohn nextgenerationuniversalhereditarycancerscreeningimplementationofanautomatedhereditarycancerscreeningprogramforpatientswithadvancedcancerundergoingtumorsequencinginalargehmo AT holmquistkimberlyj nextgenerationuniversalhereditarycancerscreeningimplementationofanautomatedhereditarycancerscreeningprogramforpatientswithadvancedcancerundergoingtumorsequencinginalargehmo AT haquereina nextgenerationuniversalhereditarycancerscreeningimplementationofanautomatedhereditarycancerscreeningprogramforpatientswithadvancedcancerundergoingtumorsequencinginalargehmo AT alvaradomonica nextgenerationuniversalhereditarycancerscreeningimplementationofanautomatedhereditarycancerscreeningprogramforpatientswithadvancedcancerundergoingtumorsequencinginalargehmo |